Use of Telemedicine for Buprenorphine Inductions in Patients With Commercial Insurance or Medicare Advantage

This cross-sectional study examines the use of telemedicine for buprenorphine inductions among individuals with commercial insurance or Medicare Advantage during the temporary repeal of the Ryan Haight Act requirement of in-person evaluation before prescribing buprenorphine during to the COVID-19 pa...

Full description

Saved in:
Bibliographic Details
Published inJAMA network open Vol. 5; no. 1; p. e2142531
Main Authors Barsky, Benjamin A, Busch, Alisa B, Patel, Sadiq Y, Mehrotra, Ateev, Huskamp, Haiden A
Format Journal Article
LanguageEnglish
Published United States American Medical Association 04.01.2022
Subjects
Adult
Aged
Aged, 80 and over
Buprenorphine - therapeutic use
COVID-19
Cross-Sectional Studies
Drug Prescriptions
Female
Humans
Insurance Coverage
Legislation, Medical
Male
Medicare Part C
Middle Aged
Narcotic Antagonists - therapeutic use
Online Only
Opioid-Related Disorders - drug therapy
Pandemics
Practice Patterns, Physicians' - legislation & jurisprudence
Research Letter
Substance Use and Addiction
Telemedicine
Telemedicine - legislation & jurisprudence
United States
Young Adult
United States
Online AccessGet full text

Cover

More Information
Summary:This cross-sectional study examines the use of telemedicine for buprenorphine inductions among individuals with commercial insurance or Medicare Advantage during the temporary repeal of the Ryan Haight Act requirement of in-person evaluation before prescribing buprenorphine during to the COVID-19 pandemic.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2574-3805
2574-3805
DOI:10.1001/jamanetworkopen.2021.42531